Antiretroviral therapy can effectively block HIV-1 replication and prevent or reverse
immunodeficiency in HIV-1-infected individuals. However, viral replication resumes within …

Therapeutic strategies are being clinically tested either to eradicate latent HIV reservoirs or
to achieve virologic control in the absence of antiretroviral therapy. Attaining this goal will …

HIV-1 persists in a latent reservoir in resting CD4+ T cells despite antiretroviral therapy
(ART). The reservoir decays slowly over the first 7 years of ART (t 1/2= 44 months). However …

The barrier to curing HIV-1 is thought to reside primarily in CD4+ T cells containing silent
proviruses. To characterize these latently infected cells, we studied the integration profile of …

The quantitative viral outgrowth assay (QVOA) provides a precise minimal estimate of the
reservoir of resting CD4+ T-cell infection (resting cell infection [RCI]). However, the variability …

Highly potent and broadly neutralizing anti-HIV-1 antibodies (bNAbs) have been used to
prevent and treat lentivirus infections in humanized mice, macaques, and humans,,,,,,,,,,,. In …

The phenotypic characterization of the cells in which HIV persists during antiretroviral
therapy (ART) remains technically challenging. We developed a simple flow cytometry …

The latent reservoir for HIV-1 in resting CD4+ T cells is a major barrier to cure. Several lines
of evidence suggest that the latent reservoir is maintained through cellular proliferation …

HIV-1 reservoirs preclude virus eradication in patients receiving highly active antiretroviral
therapy (HAART). The best characterized reservoir is a small, difficult-to-quantify pool of …

More than 75 million people worldwide have been infected with human immunodeficiency
virus (HIV), and there are now approximately 37 million individuals living with the infection …